Filtered By:
Specialty: Infectious Diseases
Vaccination: Influenza Vaccine

This page shows you your search results in order of date.

Order by Relevance | Date

Total 193 results found since Jan 2013.

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
ConclusionsBNT162b2 coadministered with SIIV elicited immune responses that were noninferior to those elicited by BNT162b2 alone and SIIV alone, and BNT162b2 had an acceptable safety profile when coadministered with SIIV. The results of this study support the coadministration of BNT162b2 and SIIV in adults.Trial RegistrationClinicalTrials.gov registration: NCT05310084.
Source: Infectious Diseases and Therapy - September 12, 2023 Category: Infectious Diseases Source Type: research

Exploring missed opportunities for influenza vaccination and influenza vaccine co-administration patterns among Italian older adults: a retrospective cohort study
CONCLUSIONS: A sizeable proportion of older adults who received other recommended vaccines during the last influenza season did not receive SIV. This share of missed opportunities, which are subject to some social inequalities, may be addressed by increasing vaccine co-administration rates and implementing tailored health promotion interventions.PMID:37632235 | DOI:10.1093/eurpub/ckad155
Source: Herpes - August 26, 2023 Category: Infectious Diseases Authors: Alexander Domnich Andrea Orsi Matilde Ogliastro Carlo-Simone Trombetta Marianna Scarpaleggia Chiara Ceccaroli Carla Amadio Anna Raffo Luca Berisso Alla Yakubovich Giacomo Zappa Daniela Amicizia Donatella Panatto Giancarlo Icardi Source Type: research

Vaccine-induced and hybrid immunity to SARS-CoV-2 after three or four doses of BNT162b2 - results from 22 months follow-up of a healthcare workers cohort, Israel, 2020-2022
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has killed at least seven million worldwide since its emergence in China in late 2019 [1] and became the most significant global health crisis since the 1918 influenza pandemic [2]. In order to mitigate the spread of the pandemic, non-pharmaceutical interventions such as protective equipment and social distancing as well as the rapid development and mass implementation COVID-19 vaccines, have been rolled out to prevent death, reduce the spread and severity of disease, and protect healthcare systems from becoming overwhelmed [2].
Source: International Journal of Infectious Diseases - August 10, 2023 Category: Infectious Diseases Authors: Michael Edelstein, Karine Wiegler Beiruti, Hila Ben-Amram, Netta Beer, Christian Sussan, Perachel Batya, Salman Zarka, Kamal Abu Jabal Source Type: research

A seesaw effect between COVID-19 and influenza during 2020-2023 in WHO regions
CONCLUSIONS: Influenza activity and former seasonal epidemiological patterns are shaken by the COVID-19 pandemic. Their activities are moderately and above inversely correlated, oppressing and competing with each other, showing a seesaw effect. In the post-pandemic era of COVID-19, the seesaw trends may be more prominent, prompting the possibility of using one another as early warning signals for future estimates and conducting optimized annual vaccine campaigns.PMID:37191650 | DOI:10.2196/44970
Source: Euro Surveill - May 16, 2023 Category: Infectious Diseases Authors: Qing Wang Mengmeng Jia Mingyue Jiang Wei Liu Jin Yang Peixi Dai Yanxia Sun Jie Qian Weizhong Yang Luzhao Feng Source Type: research

Engaging Multistakeholder Perspectives to Identify Patient-Centered Research Priorities Regarding Vaccine Uptake Among Adults With Autoimmune Conditions
CONCLUSION: A multistakeholder group identified key topics as critically important priorities for future research to decrease vaccine hesitancy and improve uptake of vaccines for adults with autoimmune conditions.PMID:37127530 | DOI:10.1002/acr2.11546
Source: Herpes - May 1, 2023 Category: Infectious Diseases Authors: Shilpa Venkatachalam Kelly Gavigan Laura Stradford Vandana Dronadula Angela Degrassi W Benjamin Nowell Shubhasree Banerjee Peter A Merkel Michael D George Jennifer Gordon Dianne G Shaw Kalen Larsen Lisa Emrich Robert N McBurney Hope Sullivan Ashira Blazer Source Type: research

Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections
Mol Biotechnol. 2023 Jan 31. doi: 10.1007/s12033-023-00679-1. Online ahead of print.ABSTRACTNovel effective drugs or therapeutic vaccines have been already developed to eradicate viral infections. Some non-viral carriers have been used for effective drug delivery to a target cell or tissue. Among them, cell penetrating peptides (CPPs) attracted a special interest to enhance drug delivery into the cells with low toxicity. They were also applied to transfer peptide/protein-based and nucleic acids-based therapeutic vaccines against viral infections. CPPs-conjugated drugs or vaccines were investigated in several viral infectio...
Source: Herpes - January 31, 2023 Category: Infectious Diseases Authors: Niloofar Khairkhah Ali Namvar Azam Bolhassani Source Type: research

Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV
Conclusion: Two doses of COVID-19 vaccine offered substantial protection against symptomatic illness and hospitalization/death in people with HIV prior to the emergence of the Omicron variant. Our findings do not support a broad conclusion that COVID-19 VE is lower among people with HIV in populations that, for the most part, are attending HIV care, taking antiretroviral medication, and are virally suppressed.
Source: AIDS - November 17, 2022 Category: Infectious Diseases Tags: FAST TRACK Source Type: research

Virus-CKB 2.0: Viral-Associated Disease-Specific Chemogenomics Knowledgebase
ACS Omega. 2022 Oct 10;7(42):37476-37484. doi: 10.1021/acsomega.2c04258. eCollection 2022 Oct 25.ABSTRACTTransmissible and infectious viruses can cause large-scale epidemics around the world. This is because the virus can constantly mutate and produce different variants and subvariants to counter existing treatments. Therefore, a variety of treatments are urgently needed to keep up with the mutation of the viruses. To facilitate the research of such treatment, we updated our Virus-CKB 1.0 to Virus-CKB 2.0, which contains 10 kinds of viruses, including enterovirus, dengue virus, hepatitis C virus, Zika virus, herpes simplex...
Source: Herpes - October 31, 2022 Category: Infectious Diseases Authors: Yixuan Hao Maozi Chen Yasmin Othman Xiang-Qun Xie Zhiwei Feng Source Type: research

Atherosclerosis by Virus Infection-A Short Review
Biomedicines. 2022 Oct 19;10(10):2634. doi: 10.3390/biomedicines10102634.ABSTRACTAtherosclerosis manifests by the thickening of artery walls and their narrowed channels through the accumulation of plaque. It is one of the most important indicators of cardiovascular disease. It can be caused by various factors, such as smoking, a high cholesterol diet, hypertension, hyperglycemia, and genetic factors. However, atherosclerosis can also develop due to infection. It has been reported that some bacteria and viruses can cause the development of atherosclerosis. Examples of these viruses are influenza viruses, herpes viruses, hep...
Source: Herpes - October 27, 2022 Category: Infectious Diseases Authors: Seang-Hwan Jung Kyung-Tae Lee Source Type: research